| http://purl.uniprot.org/citations/27100735 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/27100735 | http://www.w3.org/2000/01/rdf-schema#comment | "PurposeIn a phase III study of gemcitabine plus erlotinib for advanced pancreatic cancer conducted in Canada, the incidence of interstitial lung disease (ILD) was 3.5 %. However, the incidence of ILD was reported as high as 8.5 % in a Japanese phase II study. These results suggest the influence of ethnic factors in the association of the use of gemcitabine plus erlotinib with the incidence of ILD. Here, we conducted a prospective study to analyze the relationship between human leukocyte antigen (HLA) alleles and ILD in Japanese patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib.MethodsPatients were treated with gemcitabine (1000 mg/m(2); administered by intravenous infusion on days 1, 8, and 15 every 4 weeks) and erlotinib (given orally at 100 mg/day). We compared the frequencies of HLA alleles in patients who did and did not develop ILD.ResultsA total of 57 patients were treated, and 4 patients (7.0 %) developed ILD. The combination of HLA-B*15:01 and DRB1*15:01 was observed in 2 of 4 patients (50 %) with ILD and in only 1 of 53 patients without ILD (2 %) resulting in odds ratio of 52.0 (95 % CI 3.2-842.5; p = 0.011).ConclusionThese results suggest that the combination of HLA-B*15:01 and DRB1*15:01 is associated with ILD in Japanese patients with advanced pancreatic cancer receiving gemcitabine plus erlotinib."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.org/dc/terms/identifier | "doi:10.1007/s00280-016-3026-6"xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Nishimura M."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Saito Y."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Saito K."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Tsuji A."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Kotake T."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Minami H."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Imamura Y."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Toyoda M."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Takenaka K."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Kiyota N."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Mukohara T."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/author | "Chayahara N."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/date | "2016"xsd:gYear |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/name | "Cancer Chemother Pharmacol"xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/pages | "1165-1170"xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/title | "The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer."xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://purl.uniprot.org/core/volume | "77"xsd:string |
| http://purl.uniprot.org/citations/27100735 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/27100735 |
| http://purl.uniprot.org/citations/27100735 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/27100735 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C3H3-mappedCitation-27100735 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/27100735 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C3I1-mappedCitation-27100735 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/27100735 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C552-mappedCitation-27100735 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/27100735 |